Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dbl-Blind, Rand Phase 1/2a Human Challenge Study, to Eval Safety, Reactognty, Immunognty and Preliminary Efficacy After Sporozoite Challenge/Rechallenge of Vaccines Containing RTS,S.

Next Previous
X
Search
Trial Profile

Dbl-Blind, Rand Phase 1/2a Human Challenge Study, to Eval Safety, Reactognty, Immunognty and Preliminary Efficacy After Sporozoite Challenge/Rechallenge of Vaccines Containing RTS,S.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 257049 (Primary)
  • Indications Falciparum malaria; Malaria
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 31 Mar 2020 Results (n=45) assessing functional antibodies and protection against controlled human malaria infection challenge were published in the Journal of Infectious Diseases
    • 10 Feb 2018 Results of pooled analysis of this and other five phase II studies assessing relationship between HLA allele groups and RTS,S-mediated protection in controlled human malaria infections, published in the Vaccine.
    • 12 Jan 2010 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top